Boehringer Ingelheim has established a research alliance with the University of Toronto through the Toronto Recombinant Antibody Centre (TRAC), together with Toronto-based University Health Network, a research hospital affiliated with the University of Toronto, and Mount Sinai Hospital, an acute-care academic health sciences center affiliated with University of Toronto, to characterize new therapeutic targets in the field of ubiquitin biology. Alterations of the ubiquitin system are linked to many common diseases such as cancer, diabetes, inflammation, and several central nervous system disorders.

Under the agreement, the research capabilities of the three research institutes and Boehringer Ingelheim will be brought together to provide novel starting points for drug discovery in a multi-year research program focusing on the development and characterization of novel ubiquitin binding variants developed at the TRAC. Further details of the agreement were not disclosed.

Source: Boehringer Ingelheim